NSRX insider buying and SEC filings, explained
Nasus Pharma Ltd · CIK 2029039
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$62K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 17, 2026 | Purchase (code P) | Dan Benjamin Teleman (CEO and Director) bought 6,550 shares at $3.10 ($20K), reported as a purchase (code P). Holdings up 4% to 163,541 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 22, 2026 |
| Apr 22, 2026 | Purchase (code P) | Dan Benjamin Teleman (CEO and Director) bought 2,900 shares at $3.76 ($11K), reported as a purchase (code P). Holdings up 2% to 156,991 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 22, 2026 |
| Mar 31, 2026 | Purchase (code P) | Dan Benjamin Teleman (CEO and Director) bought 15,000 shares at $2.04 ($31K), reported as a purchase (code P). Holdings up 240% to 21,246 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 1, 2026 |
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NSRX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.